C5a, but not C3a, increases VEGF secretion in ARPE-19 human retinal pigment epithelial cells

Current Eye Research

Volumn 34, Issue 1, 2009, Pages 57-61

  Cortright, Daniel N ^a,b   Meade, Robin ^a   Waters, Stephen M ^a   Chenard, Bertrand L ^a   Krause, James E ^a  

^a NEUROGEN CORPORATION   (United States)

^b Science Foundry LLC   (United States)

Author keywords

ARPE 19; C3a; C5a; C5L2; VEGF

Indexed keywords

COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT INHIBITOR; VASCULOTROPIN; COMPLEMENT C3A RECEPTOR; COMPLEMENT RECEPTOR; MESSENGER RNA; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; COMPLEMENT SYSTEM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NUCLEOTIDE SEQUENCE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL LINE; DRUG EFFECT; GENETICS; METABOLISM; NEUTROPHIL;

CELL LINE; COMPLEMENT C3A; COMPLEMENT C5A; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEUTROPHILS; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; RETINAL PIGMENT EPITHELIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59449090281     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802546658     Document Type: Article

References (25)

1. Köhl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol. 2001;38:175-187.
2. Pellas TC, Wennogle LP. C5a receptor antagonists. Curr Pharm Des. 1999;5:737-755.
3. Holland MC, Morikis D, Lambris JD. Synthetic small-molecule complement inhibitors. Curr Opin Invest Drugs 2004;5:1164-1173.
4. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821-852.
5. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty LI, Hageman JL, Stockman HA, Borchardt JD, Gehrs KM, Smith RJ, Silvestri G, Russell SR, Klaver CC, Barbazetto I, Chang S, Yannuzzi LA, Barile GR, Merriam JC, Smith RT, Olsh AK, Bergeron J, Zernant J, Merriam JE, Gold B, Dean M, Allikmets R. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005;102:7227-7232.
6. Hageman GS, Hancox LS, Taiber AJ, Gehrs KM, Anderson DH, Johnson LV, Radeke MJ, Kavanagh D, Richards A, Atkinson J, Meri S, Bergeron J, Zernant J, Merriam J, Gold B, Allikmets R, Dean M. AMD Clinical study group. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: Characterization, ethnic distribution, and evolutionary implications. Ann Med. 2006;38:592-604.
7. Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, Clayton DG, Hayward C, Morgan J, Wright AF, Armbrecht AM, Dhillon B, Deary IJ, Redmond E, Bird AC, Moore AT. Genetic factors in AMD study group. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357:553-561.
8. Ambati J, Anand A, Fernandez S, Sakurai E, Lynn BC, Kuziel WA, Rollins BJ, Ambati BK. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med. 2003;9:1390-1397.
9. Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD, Chen Y, Zhang K, Ambati BK, Baffi JZ, Ambati J. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci USA 2006;103:2328-2333.
10. Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcòstegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann RO. European Society for Retina Specialists' Guidelines Committee (EURETINA). Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand. 2007;85:486-494.
11. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1-29.
12. Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, Albuquerque RJ, Richter E, Sakurai E, Newcomb MT, Kleinman ME, Caldwell RB, Lin Q, Ogura Y, Orecchia A, Samuelson DA, Agnew DW, St Leger J, Green WR, Mahasreshti PJ, Curiel DT, Kwan D, Marsh H, Ikeda S, Leiper LJ, Collinson JM, Bogdanovich S, Khurana TS, Shibuya M, Baldwin ME, Ferrara N, Gerber HP, De Falco S, Witta J, Baffi JZ, Raisler BJ, Ambati J. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443:993-997.
13. Brodbeck RM, Cortright DN, Kieltyka AP, Yu J, Baltazar CO, Buck ME, Meade R, Maynard GD, Thurkauf A, Chien DS, Hutchison AJ, Krause JE. Identification and characterization of NDT 9513727, a novel, orally bioavailable C5a receptor inverse agonist. J Pharmacol Exp Ther. 2008; Aug 27 [epub].
14. Szallasi A, Blumberg PM, Annicelli LL, Krause JE, Cortright DN. The cloned rat vanilloid receptor VR1 mediates both R-type binding and C-type calcium response in dorsal root ganglion neurons. Mol Pharmacol. 1999;56:581-587.
15. Ames RS, Li Y, Sarau HM, Nuthulaganti P, Foley JJ, Ellis C, Zeng Z, Su K, Jurewicz AJ, Hertzberg RP, Bergsma DJ, Kumar C. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem. 1996;271:20231-20234.
16. Slomiany MG, Rosenzweig SA. Autocrine effects of IGFI-induced VEGF and IGFBP-3 secretion in retinal pigment epithelial cell line ARPE-19. Am J Physiol Cell Physiol. 2004;287:C746-753.
17. Fukuoka Y, Medof EM. C5a receptor-mediated production of IL-8 by the human retinal pigment epithelial cell line, ARPE-19. Curr Eye Res. 2001;23:320-325.
18. Fukuoka Y, Strainic M, Medof ME. Differential cytokine expression of human retinal pigment epithelial cells in response to stimulation by C5a. Clin Exp Immunol. 2003;131:248-253.
19. Richards A, Kavanagh D, Atkinson JP. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory states the examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol. 2007;96:141-177.
20. Petrukhin K. New therapeutic targets in atrophic age-related macular degeneration. Expert Opin Ther Targets 2007;11:625-639.
21. Okinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, Kinrade MB, Brodbeck RM, Krause JE, Choe HR, Gerard NP, Gerard C. C5L2, a nonsignaling C5A binding protein. Biochemistry 2003;42:9406-9615.
22. Maslowska M, Legakis H, Assadi F, Cianflone K. Targeting the signaling pathway of acylation stimulating protein. J Lipid Res. 2006;47:643-652.
23. Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay CR, Zetoune FS, Gerard NP, Cianflone K, Köhl J, Gerard C, Sarma JV, Ward PA. Functional roles for C5a receptors in sepsis. Nat Med. 2008;14:551-557.
24. Sumichika H. C5a receptor antagonists for the treatment of inflammation. Curr Opin Invest Drugs 2004;5:505-510.
25. Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure, and therapeutic potential of complement C5a receptors. Br J Pharmacol. 2007;152:429-448.